The size of the Radiotherapy Market in Europe was worth USD 1.62 Billion in 2022 and is estimated to be growing at a CAGR of 5.71% to reach USD 2.13 billion by 2027.
Markets such as Europe are ripening with both old and new technologies. As a result, the most often arising forms of the disease in the European region are colorectal, breast, prostate, and lung cancers.
Radiotherapy is a painless treatment and is extensively used in cancer treatment. Radiotherapy is centered on the principle of damage to cancerous cells by destroying their DNA inside these cells by radiations. Thus, it slows down the growth of cancerous cells and is intended to provide supportive care to relieve the patient of symptoms.
The Europe Radiotherapy Market is driven by numeral factors like the surge in the number of cancer patients, a decrease in the cost of treatment in several developed areas, enormous government and non-government funds in Research and Development of cancer treatment, and inclination for non-invasive techniques of therapy. In radiotherapy, harm to neighboring healthy cells by the high radiation dosage is a side-effect that could risk market growth. In addition, the several side-effects of radiation treatment, such as fatigue, skin problems, nausea, fertility issues, hair loss, appetite loss, diarrhea, could obstruct radiotherapy devices' market growth.
This research report on the Europe Radiotherapy market has been segmented and sub-segmented into the following categories:
By Equipment Type:
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the European radiotherapy market profiled in this report are Nordion Inc., RaySearch Laboratories AB, Ion Beam Applications SA, C. R. Bard Inc., Mevion Medical Systems Inc., Varian Medical Systems Inc., IsoRay Medical Inc., Elekta AB, Accuray Incorporated and Mitsubishi Electric Corporation.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org